CA2979115A1 - Oligonucleotide sequences targeting transcription factor tsc22d4 for the treatment of insulin resistance - Google Patents

Oligonucleotide sequences targeting transcription factor tsc22d4 for the treatment of insulin resistance Download PDF

Info

Publication number
CA2979115A1
CA2979115A1 CA2979115A CA2979115A CA2979115A1 CA 2979115 A1 CA2979115 A1 CA 2979115A1 CA 2979115 A CA2979115 A CA 2979115A CA 2979115 A CA2979115 A CA 2979115A CA 2979115 A1 CA2979115 A1 CA 2979115A1
Authority
CA
Canada
Prior art keywords
insulin
inhibitor
insulin resistance
disease
tsc22d4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2979115A
Other languages
English (en)
French (fr)
Inventor
Stephan Herzig
Mauricio Berriel Diaz
Tobias Schafmeier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of CA2979115A1 publication Critical patent/CA2979115A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2979115A 2015-03-23 2016-02-12 Oligonucleotide sequences targeting transcription factor tsc22d4 for the treatment of insulin resistance Pending CA2979115A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15160259.6A EP3072969A1 (en) 2015-03-23 2015-03-23 Oligonucleotide sequences targeting transcription factor TSC22D4 for the treatment of insulin resistance
EP15160259.6 2015-03-23
PCT/EP2016/053050 WO2016150618A1 (en) 2015-03-23 2016-02-12 Oligonucleotide sequences targeting transcription factor tsc22d4 for the treatment of insulin resistance

Publications (1)

Publication Number Publication Date
CA2979115A1 true CA2979115A1 (en) 2016-09-29

Family

ID=52784935

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2979115A Pending CA2979115A1 (en) 2015-03-23 2016-02-12 Oligonucleotide sequences targeting transcription factor tsc22d4 for the treatment of insulin resistance

Country Status (12)

Country Link
US (2) US10676739B2 (enExample)
EP (2) EP3072969A1 (enExample)
JP (1) JP2018513841A (enExample)
KR (1) KR20170128348A (enExample)
CN (1) CN107278229A (enExample)
BR (1) BR112017016021A2 (enExample)
CA (1) CA2979115A1 (enExample)
DK (1) DK3274455T3 (enExample)
ES (1) ES2837085T3 (enExample)
MX (1) MX384193B (enExample)
RU (1) RU2723091C2 (enExample)
WO (1) WO2016150618A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7289510B2 (ja) * 2019-05-08 2023-06-12 国立大学法人高知大学 認知症治療薬のスクリーニング方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1206234A4 (en) * 1999-06-03 2005-06-01 Jessie L S Au METHODS AND COMPOSITIONS FOR MODULATING PROLIFERATION AND CELL DEATH
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
JP4869942B2 (ja) 2003-12-11 2012-02-08 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド インスリン感受性／抵抗性、糖尿病および肥満におけるｒｂｐ４
AU2005248147A1 (en) * 2004-05-11 2005-12-08 Alphagen Co., Ltd. Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
US7943306B2 (en) * 2005-01-12 2011-05-17 The Board Of Trustees Of The Leland Stanford Junior University Gene expression signature for prediction of human cancer progression
US20140227289A1 (en) 2011-05-13 2014-08-14 Stephen Michael Cohen Compounds and methods for treating insulin resistance syndrome
GB201120317D0 (en) 2011-11-24 2012-01-04 Queen Mary & Westfield College Screening method
EP2816356A1 (en) 2013-06-17 2014-12-24 Ruprecht-Karls-Universität Heidelberg Treatment of insulin resistance through inhibitors of transcription factor TSC22D4
RU2573450C1 (ru) * 2014-08-11 2016-01-20 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Способ выявления генов-мишеней для диагностики и терапии лейкозов человека

Also Published As

Publication number Publication date
EP3274455B1 (en) 2020-10-14
BR112017016021A2 (pt) 2018-03-20
RU2017131900A3 (enExample) 2019-06-10
WO2016150618A1 (en) 2016-09-29
KR20170128348A (ko) 2017-11-22
JP2018513841A (ja) 2018-05-31
EP3072969A1 (en) 2016-09-28
DK3274455T3 (da) 2020-12-14
US10676739B2 (en) 2020-06-09
US20180023078A1 (en) 2018-01-25
CN107278229A (zh) 2017-10-20
ES2837085T3 (es) 2021-06-29
MX384193B (es) 2025-03-12
RU2723091C2 (ru) 2020-06-08
RU2017131900A (ru) 2019-04-23
US20200255834A1 (en) 2020-08-13
US11053499B2 (en) 2021-07-06
EP3274455A1 (en) 2018-01-31
MX2017012231A (es) 2018-01-30

Similar Documents

Publication Publication Date Title
DK2217704T3 (en) Method to promote angionesis, vascularization or vascular repair or to inhibit tumor angionesis
EP2275545A1 (en) Use of microRNA-24 and/or its targets for the treatment and prevention of ischemia and induction of angiogenesis
JP7376873B2 (ja) がん促進因子発現抑制剤、その有効成分のスクリーニング方法、該方法に有用な発現カセット、診断薬、及び診断方法
EP2283846A1 (en) miRNA compounds for treatment of prostate carcinoma
KR102321426B1 (ko) 남성형 탈모 표적 유전자의 발현을 억제하는 비대칭 siRNA
US11053499B2 (en) Oligonucleotide sequences targeting transcription factor TSC22D4 for the treatment of insulin resistance
JP2007530431A (ja) 膵臓癌を治療するための組成物および方法
JP6479780B2 (ja) 転写因子ｔｓｃ２２ｄ４の阻害剤によるインスリン耐性の治療
EP1652917A1 (en) Rna capable of inhibiting expression of klf5 gene
JPWO2010079819A1 (ja) 肥満または糖尿病治療用医薬組成物
KR100930282B1 (ko) ＮＩＫ 유전자에 대한 ｓｉＲＮＡ 및 이를 포함하는 간질환치료제
Ren et al. Construction, modification and evaluation of apolipoprotein AI promoter-driven shRNA expression vectors against hTERT
WO2024003205A1 (en) Long non-coding rnas as target for treating fibrosis and cancer
CN102427852A (zh) 用于抑制糖皮质素受体(gcr)基因表达的组合物和方法
KR20110093840A (ko) 지방세포 형성의 조절을 위한 ｐｌａｃ８ 활성 억제제의 용도

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201222

EEER Examination request

Effective date: 20201222

EEER Examination request

Effective date: 20201222

EEER Examination request

Effective date: 20201222

EEER Examination request

Effective date: 20201222

EEER Examination request

Effective date: 20201222

EEER Examination request

Effective date: 20201222

EEER Examination request

Effective date: 20201222